Faculty Roundtable on CAR T-cell Therapies, Bispecific Antibodies & Antibody-Drug Conjugates in FL

Please use the box in the top-right corner of the screen to login or register.

Release Date: March 09, 2023
Expiration Date: March 09, 2024

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Although follicular lymphoma (FL) often responds well to initial therapy, many patients will relapse, and a considerable proportion of patients experience disease progression within 24 months. In this activity, Drs. Nastoupil and Diefenbach address the recent advances in FL-directed CAR T-cell therapies, bispecific antibodies (BsAbs), and antibody-drug conjugates (ADCs). They will also discuss safety and efficacy data from ongoing clinical trials, and how to incorporate recently approved and emerging novel targeted therapies into individualized treatment strategies.

Target Audience

This educational activity is designed for hematology/oncology physicians, advanced practice providers, nurses and pharmacists on the treatment team for patients with follicular lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the latest clinical trial data supporting CAR T-cell therapies for FL
  • Evaluate the latest clinical data and interim results of trials investigating safety and efficacy of bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs) in patients with FL
  • Describe practical strategies for individualizing treatment selection in patients with FL
  • Outline strategies for monitoring, identifying, and mitigating AEs associated with CAR T-cell therapies, BsAbs, and ADCs

Agenda

  • Faculty Roundtable on CAR T-cell Therapies, Bispecific Antibodies & Antibody-Drug Conjugates in FL – Loretta J. Nastoupil, MD and Catherine S. Diefenbach, MD 

Instructions for Participation and Credit

This activity is eligible for credit through March 09, 2024. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Loretta J. Nastoupil, MD
Associate Professor
Department of Lymphoma/Myeloma
University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Loretta Nastoupil received her medical degree from the University of Texas Southwestern Medical School. She completed her internal medicine training at Washington University and her hematology/medical oncology fellowship at Emory University. Dr. Nastoupil is an Associate Professor in the Department of Lymphoma/Myeloma at the University of Texas MD Anderson Cancer Center in Houston. In addition, she is the Deputy Chair of the Lymphoma/Myeloma Department and Section Chief of the indolent lymphoma and new drug development teams, which are in line with her research interests of designing and conducting prospective trials aimed at exploiting the immune system to eradicate B-cell lymphoma. Dr. Nastoupil is also interested in real-world evidence and has been involved in exploring outcomes among patients treated with standard of care CAR T-cell therapy.

Catherine S. Diefenbach, MD
Associate Professor, Department of Medicine at
NYU Grossman School of Medicine
Director, Hematology Translational Research and
Director, Clinical Lymphoma Program
Perlmutter Cancer Center
New York, New York

Dr. Catherine Diefenbach received her medical degree from the University of Pennsylvania School of Medicine. She completed her internship and residency at the Johns Hopkins Hospital and her hematology-oncology fellowship at Memorial Sloan Kettering Cancer Center. Dr. Diefenbach is an Associate Professor in the Department of Medicine at NYU Grossman School of Medicine. She is the Director of Hematology Translational Research and Clinical Lymphoma Program at Perlmutter Cancer Center, NYU Langone Health in New York City.

Dr. Diefenbach’s clinical practice focuses on care of patients with all types of lymphoma. Her research is both translational and clinical, and focuses on the relationship between systemic immunity, tumor microenvironment, and lymphoid malignancies. Dr. Diefenbach directs both the investigator-initiated and industry-sponsored research within the lymphoma division. Her pioneering work in lymphoma immunology and immunotherapy, and her role as a Principal Investigator in numerous clinical trials makes her a leading investigator in the fields of immunotherapy, translational research, innovative clinical trial development, and lymphoma.

Accreditation

MediCom CME CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-23-008-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
MediCom NURSING CREDIT MediCom Worldwide, Inc.is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 23-008-164

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires any person who is in a position to control the content of an accredited continuing education activity including planners, faculty, reviewers, moderators, or others to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. All relevant conflicts of interest are thoroughly vetted and mitigated prior to the commencement of the activity.

Faculty Disclosures

Dr. Loretta Nastoupil has relevant financial relationships related to advisory activities from ADC Therapeutics SA (relationship has ended), Bristol Myers Squibb Company, Caribou Biosciences, Inc., Epizyme, Inc., Genentech, Inc., Janssen Pharmaceuticals, Inc., Novartis AG, and Takeda Oncology. She has received research grants from Bristol Myers Squibb, Caribou Biosciences, Epizyme, Genentech, IGM Biosciences, Inc., Janssen Pharmaceuticals, Novartis, and Takeda Oncology.

Dr. Catherine Diefenbach has relevant financial relationships related to consulting from Epizyme, Inc., Genmab A/S, Merck & Co., Inc., and Regeneron Pharmaceuticals, Inc. She has also received consulting fees and research grants from Bristol Myers Squibb Company, Genentech - A Member of the Roche Group, MorphoSys, and Seattle Genetics, Inc., as well as a research grant from Fate Therapeutics.

All relevant conflicts of interest for these individuals have been mitigated.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee

Joan Meyer, RN, MHA, Executive Director, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies.

Peer Reviewer

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected]

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.

©2023 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242. No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please use the box in the top-right corner of the screen to login or register.

© 2024 MediCom Worldwide, Inc. All rights reserved